LIVE WEBINAR: Tuesday, September 26, 2023, 5:00 PM – 6:00 PM Eastern Time

What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma

A CME/MOC-Accredited Virtual Event

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Tuesday, September 26th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Toby A Eyre, MBChB, DipMedEd, MRCP, MD
Haematology Consultant
Honorary Senior Clinical Lecturer in Haematology
Oxford University Hospitals NHS Foundation Trust
Churchill Hospital, Headington
Oxford, United Kingdom

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by an educational grant from Lilly.

Tuesday,September 26, 2023
5:00 PM – 6:00 PM eastern time
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • Current Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma (MCL)
  • Other Novel Agents and Strategies for Patients with MCL

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of mantle cell lymphoma (MCL).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Individualize the selection and sequencing of systemic therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL), considering the patient’s clinical presentation, prior therapeutic exposure and fitness and willingness to undergo aggressive therapy.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors to better understand the resultant activity and toxicities associated with these agents.
  • Appreciate the biological rationale for, available data with and current clinical role of noncovalent BTK inhibitors for patients with R/R MCL, and discern how these agents can be appropriately integrated into routine practice.
  • Evaluate available efficacy and safety data with chimeric antigen receptor T-cell therapy directed against CD19 in R/R MCL, and identify patients eligible for this novel approach.
  • Recall ongoing clinical trials evaluating other novel approaches for R/R MCL, and obtain consent from appropriate patients for study participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr EyreAdvisory Committee: BeiGene Ltd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Roche Laboratories Inc; Consulting Agreements and Speakers Bureau: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Incyte Corporation, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, BeiGene Ltd. Dr Kahl Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Novartis, Roche Laboratories Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from Lilly.